Takeda Pharmaceutical (TAK) Other Non-Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $636.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 17.19% year-over-year to $636.5 million in Q1 2026; TTM through Mar 2026 was $636.5 million, a 17.19% increase from a year earlier, with the FY2026 full-year figure at $663.1 million, up 21.9% from the prior year.
• Other Non-Current Liabilities declined to $636.5 million in Q1 2026 per TAK's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.6 billion in Q3 2023 and bottomed at $423.1 million in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $3.5 billion (2025), against an average of $2.7 billion.
• Across the five-year window, Other Non-Current Liabilities climbed 29.75% in 2023 and dropped 25.36% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $3.3 billion in 2022, then decreased by 2.55% to $3.3 billion in 2023, then rose by 13.14% to $3.7 billion in 2024, then rose by 0.67% to $3.7 billion in 2025, then tumbled by 82.88% to $636.5 million in 2026.
• Per Business Quant, the three latest TAK Other Non-Current Liabilities figures stand at $636.5 million (Q1 2026), $3.7 billion (Q4 2025), and $3.7 billion (Q3 2025).